Radiation treatment is associated with a long-term risk of secondary malignancy in patients with cancer. External beam radiation therapy (EBRT) for the treatment of prostate cancer (PCa) in particular has been associated with the later development of bladder cancer and worse bladder cancer features. Recent data published in European Urology Focus analyzed different forms of localized PCa treatment to determine the associated long-term risks of bladder cancer. ...
Urothelial Carcinoma
Advertisement
Latest News
The novel nomogram demonstrated perfect performance in discrimination ability and clinical net benefit.
The phase 3 KEYNOTE-A39/EV-302 study has met its dual primary end points of OS and PFS in advanced or metastatic UC.
Dr. de Kouchkovsky highlights survival and response rates after ICIs and EV for patients with squamous histology.
Dr. de Kouchkovsky explains studying the impact of squamous histology on clinical outcomes in mUC after ICIs or EV.
The positive results were consistent with findings from the primary analysis, such as PFS and overall response benefit.
Anke Richters, PhD, discusses how not reporting primary end point changes in clinical trials can lead to issues.
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Dr. McKay discusses upcoming prostate cancer data to be presented at ESMO and discussed at The Uromigos: Live & Unplugged.
Dr. Gupta also discusses upcoming bladder cancer data from ESMO that will influence debate and discussion at the event.
Dr. Petros Grivas shares what data he's most looking forward to discussing at the second Uromigos: Live & Unplugged event.
The second annual Uromigos: Live & Unplugged event will take place in Nashville, Tennessee, on November 3-4.
Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC.
Drs. Shilpa Gupta and Vadim Koshkin continue on the EV-103 trial with reference to outcomes and toxicities in cohort K.
Advertisement
Advertisement
Trending
The first PET scans using Illuccix, Telix’s PSMA-PET imaging agent, have been carried out in cooperation with BAMF Health.
Few biomarkers predict therapeutic response to radiation or adjunctive treatments in PCa patients treated with radiotherapy.
Nanobubbles can target membrane proteins, including PSMA, to bind to receptors that are overexpressed in cancer cells.
